RxDoctor Payments DataLook up a doctor →

David Cahn, MD

Family Practice · San Jose, CANPI 1689762205

Payments from drug & device makers

$39,800in general payments, 2019–2025

Across 1,544 payments — averaging $25.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$12K
  • AbbVie$4K
  • GSK$2K
  • AstraZeneca$2K
  • Pfizer$2K
  • Novo Nordisk$2K
  • plus $16K from 54 others

What the payments were for

  • Speaking & faculty fees$9,00023%
  • Travel & lodging$1,6784%
  • Food & beverage$28,57672%
  • Education$5471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen104$12,095
AbbVie(2 entities)302$4,347
GSK95$1,998
AstraZeneca(2 entities)74$1,724
Pfizer90$1,637
Novo Nordisk105$1,543
Kowa Pharmaceuticals America, Inc.85$1,323
Janssen Research & Development, LLC4$1,165
Lilly USA, LLC64$929
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)42$905
Astellas Pharma US Inc36$881
Boehringer Ingelheim70$827
Mylan Specialty L.p.32$785
Radius Health, Inc.31$726
Merck37$676
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC28$459
Abbott17$451
Otsuka America Pharmaceutical, Inc.20$405
Sumitomo Pharma America, Inc.31$388
Novartis17$369
Sanofi-aventis U.S. LLC11$344
Bayer14$332
Axsome Therapeutics, Inc.12$306
Exact Sciences14$304
Teva Pharmaceuticals USA, Inc.8$285
IBSA Pharma Inc.14$283
Vanda Pharmaceuticals Inc.12$263
Idorsia Pharmaceuticals US Inc9$204
Hikma Pharmaceuticals USA12$202
Avanir Pharmaceuticals, Inc.8$186
Neurocrine Biosciences, Inc.8$182
Dexcom, Inc.7$165
Madrigal Pharmaceuticals4$137
E.r. Squibb & Sons, L.L.C.3$134
Nestle Healthcare Nutrition Inc.5$131
Takeda Pharmaceuticals U.S.A., Inc.6$130
Amarin Pharma, Inc.1$129
Boston Scientific2$122
Philips North America LLC5$113
Amneal Pharmaceuticals LLC5$112
Viiv Healthcare Company6$110
Corium, LLC4$108
Johnson & Johnson5$107
Sanofi Pasteur Inc.4$106
Esperion Therapeutics, Inc.5$105
Arbor Pharmaceuticals, Inc.5$105
Phathom Pharmaceuticals, Inc.4$99
Biohaven Pharmaceutical Holding Company Ltd.4$90
Jazz Pharmaceuticals Inc.5$89
Alfasigma USA, Inc.4$85
Eisai Inc.4$70
Zyla Life Sciences, Inc.4$67
Medtronic(3 entities)3$63
Painteq LLC1$63
Gilead4$62
Intercept Pharmaceuticals, Inc.2$55
Biohaven Pharmaceuticals, Inc.2$46
Seqirus USA Inc2$45
Electromed, Inc.3$45
Bausch Health US, LLC2$44

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,800 in reported general payments places this provider in the 95th percentile of 2,195 family practice providers in California.

See all family practice providers in California

Medicare billing

Part B allowed, 2024
$226,731
Medicare patients
269
Services billed
2,040

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide198$241,304
Repatha SureclickEvolocumab233$236,702
MounjaroTirzepatide99$133,284
JardianceEmpagliflozin111$126,410
OxycontinOxycodone Hcl22$102,300
EliquisApixaban80$91,801
FarxigaDapagliflozin Propanediol86$82,127
Trelegy ElliptaFluticasone/Umeclidin/Vilanter99$65,355
KerendiaFinerenone42$53,269
ZenpepLipase/Protease/Amylase16$53,149
VascepaIcosapent Ethyl77$51,330
VraylarCariprazine Hcl29$46,474
AptiomEslicarbazepine Acetate33$40,119
RytaryCarbidopa/Levodopa30$38,659
TymlosAbaloparatide11$37,696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,543$241,304198 claims
Lilly USA, LLCMounjaro, Trulicity$929$164,278115 claims
Boehringer IngelheimJardiance, Tradjenta$827$138,238127 claims
PfizerEliquis$1,637$91,80180 claims
AstraZenecaFarxiga$1,724$82,12786 claims
GSKTrelegy Ellipta, Breo Ellipta$1,998$77,435126 claims
AbbVieVraylar, Linzess, Synthroid, Namzaric$4,347$75,070169 claims
BayerKerendia$332$53,26942 claims
Amneal Pharmaceuticals LLCRytary$112$38,65930 claims
Radius Health, Inc.Tymlos$726$37,69611 claims
Sumitomo Pharma America, Inc.Gemtesa$388$27,80937 claims
MerckJanuvia$676$26,93528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,195 family practice providers in California.

Other family practice in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →